

## Astellas Pharma opens office in Singapore

12 December 2013 | News | By BioSpectrum Bureau



**Singapore:** Astellas Pharma, Japan's pharmaceutical giant with net sales of \$10.7 billion and net income of \$881 million as at March 31, 2013, has opened its office in Singapore.

Astellas was formed in 2005 from the merger of Yamanouchi Pharmaceutical and Fujisawa Pharmaceutical. Today, Astellas is creating innovative new drugs by leveraging on its R&D capabilities.

Mr Yoshihiko Hatanaka, president and CEO of Astellas, said, "Astellas has a business model named Global Category Leader (GCL) based on which we established a competitive edge as a leader in multiple categories of innovative medicines such as urology and transplantation. Astellas is also focusing on establishing oncology as the third GCL area. The opening of our Singapore office is important as we would like to have our products and services delivered easily to patients in this area".

Singapore is home to more than 30 of the world's leading biomedical sciences companies, leveraging on Singapore as a key home base to drive innovation.

Mr Yeoh Keat Chuan, MD, Singapore Economic Development Board (SEDB), said, "We are delighted that Astellas has established its sales office in Singapore. Singapore will continue to build on and strengthen our talent and infrastructure to enable companies to drive their business growth".

Astellas Singapore is newly established and this will be the 10th office in the the Asia/Oceania region. It will mainly commercialise Astellas' global products in Singapore, Malaysia and Brunei.

"The opening of the Singapore office is an important milestone for Astellas. This is because Singapore has built a good foundation in science and capabilities in translational and clinical research. By setting up an office in Singapore, Astellas will be able to offer innovative drugs for unmet medical needs. This is in line with one of Astellas' raison d'Ãatre which is to contribute toward improving the health of people around the world through the provision of innovative and reliable pharmaceutical products." added Mr Hiroshi Hamaguchi, MD, Astellas Singapore.